Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Clinical studies to date have failed to establish therapeutic benefit of glial cell-derived neurotrophic factor (GDNF) in Parkinson's disease (PD). In contrast to previous nonclinical neuroprotective reports, this study shows clinically relevant and long-lasting regeneration of the dopaminergic system in rhesus macaques lesioned with 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine 3-6 months before GDNF gene delivery (AAV2-GDNF). The observed progressive amelioration of functional deficits, recovery of dopamine, and regrowth of fibers to the striatal neuropil demonstrate that high GDNF expression in the putamen promotes restoration of the dopaminergic system in a primate model of advanced PD. Extensive distribution of GDNF within the putamen and transport to the severely lesioned substantia nigra, after convection-enhanced delivery of AAV2-GDNF into the putamen, indicates anterograde transport via striatonigral connections and is anticipated to occur in PD patients. Overall, these data demonstrate nonclinical neurorestoration after putaminal infusion of AAV2-GDNF and suggest that clinical investigation in PD patients is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · cited 2×
“, 2006), with efficacy results that have proven to be highly predictive of clinical improvements observed in two independent phase I human studies (Eberling et al., 2008; Christine et al., 2009; Muramatsu et al., 2009).”
BackgroundSelf-citationResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 2×
“, 2006), with efficacy results that have proven to be highly predictive of clinical improvements observed in two independent phase I human studies (Eberling et al., 2008; Christine et al., 2009; Muramatsu et al., 2009).”
BackgroundSelf-citationA phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease
Muramatsu, S.-I., Fujimoto, K.-I., Kato, S., Mizukami, H., Asari, S., Ikeguchi, K., Kawakami, T., Urabe, M., Kume, A., Sato, T., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.135 · Cited by 344
Su, X., Kells, A. P., Salegio, E. A., Richardson, R. M., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.114 · Cited by 82 · cited 2×
“To ensure optimal delivery in clinical studies, we have extensively evaluated imageguided positioning of reflux-resistant infusion cannula with realtime MR imaging of AAV2-GDNF distribution during CED (Fiandaca et al., 2008; Su et al., 2010).”
BackgroundMethodSelf-citationControlled dissemination of AAV vectors in the primate brain
Varenika, V., Kells, A. P., Valles, F., Hadaczek, P., Forsayeth, J., & Bankiewicz, K. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17511-8 · Cited by 33 · cited 1×
“To facilitate translation from NHP to clinical studies, our group has invested considerable effort in the development of reflux-resistant cannulae and infusion protocols that enable delivery of clinically relevant volumes to precisely targeted structures within the brain (Varenika et al., 2009).”
Self-citation
Cited by
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
“In a study of intraputamenal CED of AAV2-GDNF in rhesus monkeys 3 to 6 months following MPTP lesioning, Kells and colleagues observed widespread expression of GDNF within the putamen, improvement in locomotor function, anterograde transport of GDNF to the substantia nigra and rescue of dopaminergic neuronal axons (Kel…”
BackgroundAdeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
“Clinically relevant effects were also obtained in rhesus macaques, where GDNF overexpression promoted restoration of the dopaminergic system in these regions.(99,100) Another strategy often used in gene therapies for PD consists in overexpressing the enzyme aromatic L-amino acid decarboxylase (AADC).”
BackgroundGene Therapy for Neurodegenerative Diseases
Sudhakar, V., & Richardson, R. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00694-0 · Cited by 212
T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery
Richardson, R. M., Gimenez, F., Salegio, E. A., Su, X., Bringas, J., Berger, M. S., & Bankiewicz, K. S. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318217217e · Cited by 38
Self-citation
Metadata
- Authors
- Kells, A. P., Eberling, J., Su, X., Pivirotto, P., Bringas, J., Hadaczek, P., Narrow, W. C., Bowers, W. J., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S.
- Venue
- Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-07-14
- Volume
- 30
- Issue
- 28
- Pages
- 9567-9577
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1970393643
- Cited by
- 133
- References
- 6
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF. https://app.cochat.ai/papers/10.1523/jneurosci.0942-10.2010
- The paper
- Kells, A. P., Eberling, J., Su, X., Pivirotto, P., Bringas, J., Hadaczek, P., Narrow, W. C., Bowers, W. J., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S. (2010). Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF. Journal of Neuroscience. https://doi.org/10.1523/jneurosci.0942-10.2010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.